Skip to main content
. Author manuscript; available in PMC: 2016 May 2.
Published in final edited form as: Microcirculation. 2013 Feb;20(2):158–169. doi: 10.1111/micc.12014

Figure 3.

Figure 3

PMMTM exposure alters vasoreactivity in vivo. (A) Panel (1): PMMTM exposure did not alter basal vasoreactivity to metabolic dilators. Panel (2): Inhibition of NOS impairs vasodilation in sham, but not in exposed animals following AH. (B) Panel (1): PMMTM exposure did not alter responsiveness to sympathetic arteriole constriction during normal PSS superfusion. Panel (2): PMMTM exposure increased sensitivity to α-adrenergic blockade during sympathetic arteriole constriction. *p < 0.05 vs. normal superfusate at the same frequency, #p < 0.05 vs. sham. †p < 0.05 vs. PMMTM-treated normal superfusate.